CPRT heads into its September 3 earnings date with a contradictory setup: the stock is up 19% over the past month and 5.8% this week alone, yet short sellers have been quietly rebuilding positions rather than covering.
The short book is now moving in the opposite direction from the share price. Short interest climbed another 5.5% on Tuesday, pushing the total to 4.5% of the free float — up 14.9% from a month ago. That's a steady, deliberate rebuild, not a panic. What makes it notable is the context: this same short book had been easing after the post-earnings rally in mid-August, and the prior note flagged signs of tentative covering. That trend has now reversed. Bears appear to be re-engaging above $33, betting the post-earnings enthusiasm has run its course ahead of the formal September 3 Q1 results announcement. The borrow market offers no constraint on that thesis — availability is extraordinarily loose at over 8,000%, meaning lending supply dwarfs demand by a factor of roughly 80 to one, and cost to borrow has collapsed to just 0.08%, a fraction of where it traded all month. There is nothing in the lending market to force shorts to cover. Options positioning stays relaxed, with the put/call ratio at 0.54, barely above its 20-day average and well inside the year's range — no sign of institutional hedging pressure building ahead of the print.
The Street remains cautiously skeptical of where the stock is trading. Barclays trimmed its already-bearish Underweight target again this week, moving it from $26 to $25 — the third cut from the same analyst in less than a year, and now sitting 25% below the current price. Stephens held its Equal-Weight at $35 last week. The consensus mean sits at $40.20, which implies modest upside from current levels but reflects a range of views: Baird holds an Outperform with a $48 target, while Barclays anchors the bear camp well below the tape. Freedom Broker initiated with a Buy and a $39 target back in June. The direction of travel in analyst revisions has been downward over the past six months — most moves have been target cuts — which makes the stock's 19% monthly rally look like it's running ahead of fundamental conviction on the Street. The PE multiple has drifted up to roughly 17.7x, with the EV/EBITDA around 11.7x, both compressing modestly in absolute terms but rising relative to where the stock was trading a month ago given the price move.
Insider activity adds a quietly consistent cautionary note. CEO Jeff Liaw sold roughly $846,000 of stock on July 28, continuing a pattern of quarterly sales at progressively lower prices — $40.17 in January, $33.18 in April, $30.49 in July. The cadence looks programmatic rather than opportunistic, but the direction is unambiguously one-way. A board member sold $2.2 million of shares in July as well. Net insider sales over the past 90 days total just over $3 million. None of the trades carry high significance scores, but the absence of any buying from anyone inside the company is worth registering against a backdrop of the stock bouncing hard.
The most recent comparable earnings reaction offers limited reassurance. The May print delivered a 2.3% next-day gain and barely held it over the following week. The print before that saw a 1.9% one-day drop before recovering. Neither reaction was dramatic in either direction, which at least argues against positioning for a blowup — but it also suggests the stock doesn't historically run hard on results alone. With the formal September 3 event now one week away, the key question is whether the re-emerging short book is front-running a disappointing volume picture, or simply fading a rally that outpaced the fundamentals.
See the live data behind this article on ORTEX.
Open CPRT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
